As issued patents on induced pluripotent stem (iPS) cells stack up, the specter of a patent thicket looms. Michael Eisenstein investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
09 July 2010
In the version of the article originally published, it was stated that the Cohen-Boyer patents generated hundreds of billions of dollars in licensing revenue. It should have read hundreds of millions of dollars. The error has been corrected in the HMTL and PDF versions of the article.
References
Takahashi, K. & Yamanaka, S. Cell 126, 663–676 (2006).
Vierbuchen, T. et al. Nature 463, 1035–1041 (2010).
Vrtovec, K.T. & Scott, C.T. Nat. Biotechnol. 26, 393–395 (2008).
Zhou, H. et al. Cell Stem Cell 4, 381–384 (2009).
Lin, T. et al. Nat. Methods 6, 805–808 (2009).
Yu, J. et al. Science 324, 797–801 (2009).
Zhou, Q. et al. Nature 455, 627–632 (2008).
Feldman, M.P., Colaianni, A. & Liu, C.K. in Intellectual Property Management in Health and Agricultural Innovation: a Handbook of Best Practices (eds. Krattiger, A. et al.) 1797–1807 (Concept Foundation, Bangkok, 2007) http://www.iphandbook.org/handbook/ch17/p22/
Author information
Authors and Affiliations
Supplementary information
Supplementary Text and Figures
Supplementary Table 1 (PDF 73 kb)
Rights and permissions
About this article
Cite this article
Eisenstein, M. Up for grabs. Nat Biotechnol 28, 544–546 (2010). https://doi.org/10.1038/nbt0610-544
Issue Date:
DOI: https://doi.org/10.1038/nbt0610-544
This article is cited by
-
Geron trial resumes, but standards for stem cell trials remain elusive
Nature Biotechnology (2010)
-
Erratum: Up for grabs
Nature Biotechnology (2010)
